SCHEMBL197410

SCHEMBL197410

C[Si](C)(C)Oc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
CYP2A6 P11509 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2C9 P11712 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
MAPT P10636 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9388501 0.93 NPSR1 (0.44) CYP1A2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL4763549 0.86 CA1 (0.39) MEN1KMT2ACA1CA2CA9
SCHEMBL17881929 0.78 ESR2 (0.39) NPC1RAB9ASMN1; SMN2HPGDKMT2A
SCHEMBL9115160 0.78 ALDH1A1 (0.41) LMNAMAOANPC1RAB9ASMN1; SMN2
SCHEMBL9714337 0.78 ESR2 (0.39) NPC1RAB9ASMN1; SMN2HPGDKMT2A
SCHEMBL28950890 0.77 PREP (0.46) MAOAMAOBCYP1A2CYP2C19CYP2C9
SCHEMBL11233031 0.76 CA1 (0.61) CYP2A6CYP1A2CYP2C9NPC1RAB9A
SCHEMBL2016960 0.76 ACHE (0.50) LMNACYP2C9NPC1RAB9ASMN1; SMN2
SCHEMBL10879582 0.75 HPGD (0.41) LMNACYP2A6MAOAMAOBCYP1A2
SCHEMBL10406632 0.75 CA1 (0.40) LMNACYP2A6MAOAMAOBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114702372-B Method for preparing 4- (2-methoxyl) ethylphenol 台州市前进化工有限公司 2022-12-16 CN disclosed
CN-114702372-A Method for preparing high-purity 4- (2-methoxy) ethylphenol 台州市前进化工有限公司 2022-07-05 CN disclosed
US-9908908-B2 Tenofovir prodrug and pharmaceutical uses thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2018-03-06 US disclosed
EP-2891658-B1 TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) 2017-05-31 EP disclosed
US-20150225433-A1 TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2015-08-13 US disclosed
EP-2891658-A1 TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) 2015-07-08 EP disclosed
CN-103193606-B Synthesis method of brominated phenolic compound HARBIN INST OF TECHNOLOGY 2015-04-08 CN disclosed
CN-103193606-A Synthesis method of brominated phenolic compound HARBIN INST OF TECHNOLOGY 2013-07-10 CN disclosed
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-8088883-B2 Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED 2011-02-24 US disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 US disclosed
CN-101772508-A Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL CO 2010-07-07 CN disclosed
EP-2192124-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-06-02 EP disclosed
EP-2172470-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-04-07 EP disclosed
US-5998509-A BLEND OF AN EPOXY RESIN, POLYSILOXANE CURING AGENT AND FILLER KABUSHIKI KAISHA TOSHIBA (JP) 1999-12-07 US disclosed
US-5622784-A WATERPROOFING; MODIFIED SILICON DIOXIDE THIN FILM SEIKO EPSON CORPORATION (JP) 1997-04-22 US disclosed
EP-0342494-B1 Light-sensitive composition and process for the formation of relief patterns BASF AG (DE) 1993-12-29 EP disclosed
US-5069998-A RADIATION SENSITIVE MIXTURE AND PRODUCTION OF RELIEF PATTERNS BASF AKTIENGESELLSCHAFT (DE) 1991-12-03 US disclosed
EP-0342494-A2 Light-sensitive composition and process for the formation of relief patterns BASF Aktiengesellschaft (DE) 1989-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP1M1 LMNA 2664/4885CYP2A6 878/4885MAOA 278/4885
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 LMNA 3345/4885CYP2A6 490/4885MAOA 489/4885
US-20150225433-A1 TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF SLC10A1, HPRT1, SLC5A1 LMNA 2108/4885CYP2A6 55/4885MAOA 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.